

Table 11.5 Spironolactone Formulation Screening

Formulation	Spironolactone content (%)			
	Reservoir fluid	Skin	Surface wash	Total recovery
Control ^a	0.0	1.0	95.6	96.6
1	0.0	2.3	94.1	96.4
2	0.0	21.4	74.4	95.8
3	0.0	3.5	96.1	99.6
4	0.0	3.1	93.0	96.1

^acontrol = 0-hr application time (system verification); 1-4 = 48-hr application time.

HLPC assay for spironolactone only.

Table 11.6 Percutaneous Absorption of Spironolactone

In Vitro (human skin)	Total percent dose (n = 11)			
	Skin	Receptor fluid	Surface wash	Total
	2.4 ± 2.0	0.06 ± 0.07	89.7 ± 14.5	92.2 ± 14.5
In Vivo				
Rhesus monkey	2.9 ± 3.2	(24-hr skin application time)		
Man	0.5 ± 0.4	(8-hr skin application time)		